IN10018 Combination Therapy in Treatment-naïve ES-SCLC

NCT06030258 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: IN10018
DRUG: Tislelizumab
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

InxMed (Shanghai) Co., Ltd.